Veppanu (vepdegestrant) coverage guide: the first PROTAC degrader for ER+/HER2− breast cancer

On May 1, 2026, the FDA approved vepdegestrant (Veppanu) for the treatment of adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2−), ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. The approval marks the first time the FDA has approved a PROteolysis TArgeting Chimera (PROTAC) — a heterobifunctional protein degrader.

This coverage guide is for oncology access teams, pharmacists, specialty pharmacy professionals, and payer strategists who need to understand Veppanu's regulatory status, clinical evidence, formulary positioning, prior authorization requirements, and patient assistance pathways.

What Veppanu is and how it differs from existing SERDs

Veppanu is an oral selective estrogen receptor degrader (SERD) that uses PROTAC technology to recruit the E3 ligase cereblon, triggering ubiquitination and proteasomal degradation of the estrogen receptor protein. Unlike conventional SERDs (fulvestrant, elacestrant) that inhibit ER signaling, vepdegestrant actively destroys the receptor protein.

Key distinctions:

Veppanu is the only PROTAC-approved therapy in any indication. Its oral dosing eliminates the intramuscular injection required by fulvestrant, which is a meaningful convenience advantage in the advanced-disease setting.

Clinical evidence: VERITAC-2

The FDA approval was based on the phase 3 VERITAC-2 trial (NCT05654623), a global, randomized, open-label study comparing vepdegestrant to fulvestrant in patients with ER+/HER2− advanced or metastatic breast cancer.

Efficacy in the ESR1-mutated population (n=270):

• Vepdegestrant reduced the risk of disease progression or death by 43% versus fulvestrant (hazard ratio 0.57)
• Median progression-free survival (PFS): 5.0 months for vepdegestrant vs. 2.1 months for fulvestrant
• Objective response rate: 19% (vepdegestrant) vs. 4% (fulvestrant)
• Overall survival data remain immature, with 16% of deaths in the ESR1-mutated population at the time of the PFS analysis

Results were presented at the 2025 ASCO Annual Meeting and simultaneously published in the New England Journal of Medicine on May 31, 2025.

Companion diagnostic requirement

The FDA concurrently approved Guardant360 CDx as a companion diagnostic device to identify patients with breast cancer harboring ESR1 mutations for treatment with vepdegestrant.

ESR1 mutations develop in up to 40% of ER+/HER2− advanced breast cancers after exposure to aromatase inhibitors. These mutations (most commonly Y537S and D538G) cause ligand-independent ER activation, driving resistance to standard endocrine therapy.

Access implication: Prescribers must order Guardant360 CDx (a liquid biopsy test) and receive a positive ESR1-mutation result before initiating a prior authorization for Veppanu. Access teams should:

1. Ensure liquid biopsy ordering workflows are established at the point of care
2. Verify that the patient's insurance covers Guardant360 CDx (most major commercial plans and Medicare cover FDA-approved companion diagnostics)
3. Document the ESR1-mutation result in the prior authorization submission

NCCN guidelines

On May 8, 2026 — one week after FDA approval — the National Comprehensive Cancer Network (NCCN) added vepdegestrant to the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer as a Category 2A treatment option. The recommendation covers patients with hormone receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after at least one line of endocrine therapy plus a CDK4/6 inhibitor.

NCCN Category 2A status means the recommendation is based on uniform NCCN consensus that the intervention is appropriate, which strengthens the case during prior authorization and appeals.

Prior authorization and formulary positioning

As a newly approved targeted oncology therapy with a companion diagnostic requirement, Veppanu will be managed under specialty pharmacy benefit designs. Based on early payer behavior for similar agents (elacestrant, capivasertib, alpelisib):

Expected prior authorization criteria:

• Diagnosis of ER+/HER2− advanced or metastatic breast cancer
• Documented ESR1 mutation via FDA-authorized companion diagnostic (Guardant360 CDx)
• Disease progression following at least one line of endocrine therapy
• Prior CDK4/6 inhibitor use (aligned with NCCN Category 2A guideline)
• Prescriber is an oncologist or qualified specialist

Formulary tier expectation:

• Commercial plans: Specialty tier (Tier 4/5) with prior authorization
• Medicare Part D: Specialty tier; may be subject to step therapy through fulvestrant on some plans
• Medicaid: Prior authorization required; state Medicaid programs may impose additional criteria

Timing. Most commercial payers update formularies on a quarterly cycle. Because Veppanu was approved on May 1, 2026, and already has NCCN Category 2A status, Q3 2026 formulary additions are likely for most major plans. Until then, coverage will depend on individual prior authorization submissions and medical necessity reviews.

Patient assistance

Pfizer (the co-developer) offers the PfizerForAll program, which may provide financial assistance for eligible patients prescribed vepdegestrant. Patients with commercial insurance who are denied coverage or face high out-of-pocket costs should be directed to:

• PfizerForAll: https://www.pfizerforall.com
• Rigel Pharmaceuticals (the newly licensed commercial partner) is expected to establish additional patient support infrastructure in the second half of 2026

Commercial ownership and distribution

On May 12, 2026, Rigel Pharmaceuticals entered an exclusive global licensing agreement with Arvinas and Pfizer to develop, manufacture, and commercialize Veppanu. The transition of commercial responsibilities from Arvinas/Pfizer to Rigel is subject to regulatory clearance and may affect distribution channel setup, specialty pharmacy network designation, and patient support program enrollment in the near term.

Access teams should confirm which specialty pharmacies are in-network for Veppanu through the Rigel patient support program once it becomes operational. During the transition period, Arvinas/Pfizer distribution channels remain active.

Dosing and administration

• Recommended dose: 200 mg orally once daily with food
• Treatment continues until disease progression or unacceptable toxicity
• Monitor for QT prolongation, liver function abnormalities, and electrolyte disturbances
• Common adverse reactions (≥10%): fatigue, nausea, decreased appetite, musculoskeletal pain, constipation; common laboratory abnormalities include decreased white blood cells, decreased hemoglobin, decreased neutrophils, increased liver function tests (AST/ALT), decreased blood potassium, increased bilirubin, and decreased platelets

What access teams should do now

1. Update ESR1 testing workflows to include Guardant360 CDx ordering at the time of disease progression on endocrine therapy. The companion diagnostic result is a prerequisite for prior authorization.
2. Submit prior authorization with NCCN Category 2A documentation. Include the Guardant360 CDx ESR1-mutation report, treatment history showing prior endocrine therapy and CDK4/6 inhibitor use, and a reference to the NCCN guideline update from May 8, 2026.
3. Monitor the Rigel commercial launch. The licensing transition may change specialty pharmacy networks. Confirm distribution channels before submitting prescriptions.
4. Track confirmatory data. Overall survival data from VERITAC-2 remain immature. Updated OS results could influence NCCN category upgrades and payer confidence in coverage.

Sources

• FDA. FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer. May 1, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-vepdegestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast
• Arvinas Inc. Arvinas Announces FDA Approval of VEPPANU (vepdegestrant). Press release, May 1, 2026. https://ir.arvinas.com/news-releases/news-release-details/arvinas-announces-fda-approval-veppanu-vepdegestrant-treatment
• Rigel Pharmaceuticals. Rigel Enters Exclusive Global Licensing Agreement for VEPPANU. Press release, May 12, 2026. https://www.rigel.com/investors/news-events/press-releases/detail/437
• Breastcancer.org. FDA Approves Vepdegestrant for Metastatic ER-Positive Breast Cancer. Updated May 12, 2026. https://www.breastcancer.org/treatment/hormonal-therapy/vepdegestrant
• Nature Reviews Drug Discovery. First PROTAC gains FDA approval. May 2026. https://www.nature.com/articles/d41573-026-00078-6
• Drugs.com. Veppanu FDA Approval History. https://www.drugs.com/history/veppanu.html
• Targeted Oncology. FDA Approves Vepdegestrant for ESR1-Mutated ER+/HER2 Advanced Breast Cancer. May 2026. https://www.targetedonc.com/view/fda-approves-vepdegestrant-for-esr1-mutated-er-her2-advanced-breast-cancer-69-characters-